Empresas Copec S.A. (SNSE:COPEC)

Sage Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	28,244	28,115	28,528	28,613	24,787	18,059
Revenue Growth (YoY)	-0.24%	-1.45%	-0.30%	15.44%	37.25%	-23.85%
Cost of Revenue	23,632	23,508	24,560	23,318	19,955	15,129
Gross Profit	4,612	4,607	3,968	5,295	4,832	2,930
Selling, General & Admin	2,775	2,706	2,705	2,641	2,301	2,083
Other Operating Expenses	128.11	137.38	147.67	104.27	74.92	21.72
Operating Expenses	2,903	2,843	2,853	2,745	2,376	2,105
Operating Income	1,709	1,764	1,115	2,550	2,455	825.61
Interest Expense	-533.08	-550.23	-620.1	-344.08	-315.45	-375.62
Interest & Investment Income	105.77	120.81	181.33	108.12	65.61	44.43
Earnings From Equity Investments	273.58	231.18	241.06	189.47	219.2	-25.23
Currency Exchange Gain (Loss)	15.46	-15.99	-187.21	-33.72	6.13	-26.15
Other Non Operating Income (Expenses)	-125.04	-108.14	-82.27	-120.74	-68.34	-39.93
EBT Excluding Unusual Items	1,446	1,441	647.54	2,349	2,362	403.11
Merger & Restructuring Charges	-30.49	-32.29	-191.9	-83.62	-23.8	-39.34
Gain (Loss) on Sale of Investments	355.12	354.08	-	-	72.97	-
Gain (Loss) on Sale of Assets	24.57	24.48	36.51	99.79	250.02	31.7
Asset Writedown	-210.81	-215.42	-213.8	-483.44	-220.99	-82.44
Other Unusual Items	-49.2	-28.4	-37.55	-32.8	-40.63	-21.02
Pretax Income	1,550	1,561	446.5	1,852	2,402	296.03
Income Tax Expense	384.25	375.49	145.66	386.94	553.14	90.04
Earnings From Continuing Operations	1,166	1,186	300.84	1,465	1,849	205.99
Earnings From Discontinued Operations	-18.81	-19.6	91.77	58.23	-	-
Net Income to Company	1,147	1,166	392.61	1,523	1,849	205.99
Minority Interest in Earnings	-55.55	-54.99	-43.71	-57.09	-67.89	-15.33
Net Income	1,092	1,111	348.89	1,466	1,781	190.65
Net Income to Common	1,092	1,111	348.89	1,466	1,781	190.65
Net Income Growth	158.86%	218.48%	-76.20%	-17.68%	834.13%	10.83%
Shares Outstanding (Basic)	1,300	1,300	1,300	1,300	1,300	1,300
Shares Outstanding (Diluted)	1,300	1,300	1,300	1,300	1,300	1,300
EPS (Basic)	0.84	0.85	0.27	1.13	1.37	0.15
EPS (Diluted)	0.84	0.85	0.27	1.13	1.37	0.15
EPS Growth	158.86%	218.48%	-76.20%	-17.68%	834.13%	10.83%
Free Cash Flow	345.17	831.98	232.29	-512.88	164.7	126.01
Free Cash Flow Per Share	0.27	0.64	0.18	-0.40	0.13	0.10
Dividend Per Share	-	-	0.136	0.520	0.713	0.049
Dividend Growth	-	-	-73.88%	-27.13%	1370.72%	14.12%
Gross Margin	16.33%	16.39%	13.91%	18.51%	19.49%	16.23%
Operating Margin	6.05%	6.27%	3.91%	8.91%	9.91%	4.57%
Profit Margin	3.86%	3.95%	1.22%	5.12%	7.18%	1.06%
Free Cash Flow Margin	1.22%	2.96%	0.81%	-1.79%	0.66%	0.70%
EBITDA	2,573	2,621	1,956	3,233	3,115	1,522
EBITDA Margin	9.11%	9.32%	6.86%	11.30%	12.57%	8.43%
D&A For EBITDA	863.86	856.99	841.35	683.21	660.08	696.14
EBIT	1,709	1,764	1,115	2,550	2,455	825.61
EBIT Margin	6.05%	6.27%	3.91%	8.91%	9.91%	4.57%
Effective Tax Rate	24.79%	24.05%	32.62%	20.89%	23.03%	30.42%

Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.